There was no significant difference in CD19+CD27+IgD− B cells between patients with CLL 55.37% (61.18–53.51) and control group 43.26% (55.29–41.02), p = 0.0652 (Fig. 2F). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.